Volume 1.20 | Jun 4

Prostate Cell News 1.20, June 4, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer
In this study, aldehyde dehydrogenase activity was used as a basis to isolate and compare subpopulations of primary human prostate cancer cells and cell lines. [Cancer Res]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies
 
 
WATCH THE VIDEO STEMCELL Technologies Inc
 



SCIENCE NEWS

Mayo Clinic Research Finds Surgery Outperforms Drug Therapy in Treatment of Benign Prostatic Hyperplasia
A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study. [Press release from the Mayo Clinic discussing research presented at the American Urological Association 2010 Annual Meeting]

Nanoparticle PSA Test Predicts if Prostate Cancer Will Return
New research shows that an ultrasensitive PSA test using nanoparticle-based technology may be able to definitively predict after surgery if the cancer is cured long term or if it will recur. [Press release from the Northwestern University Feinberg School of Medicine discussing research presented at the American Urological Association 2010 Annual Meeting]

New Technique Detects Enzyme Implicated in Cancer, Atherosclerosis
An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis – cathepsin K – eluded reliable detection in laboratory experiments in the past. Now, a research team has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography. [Press release from the Georgia Institute of Technology discussing online prepublication in Analytical Biochemistry]

Thymoquinone Induced Oxidative Stress Targets Highly Aggressive Prostate Cancers
Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone, a major component of black seed oil (Nigella sativa), can suppress the growth of several aggressive prostate cancer cell lines, in vitro. [Press release from EurekAlert! discussing online prepublication in Experimental Biology and Medicine]

Calcium Consumption May Cause Prostate Cancer in Chinese
Among Chinese men, calcium consumption – even at relatively low levels and from non-dairy food sources such as soy, grains and green vegetables – may increase prostate cancer risk, according to results. [Press release from EurekAlert! discussing online prepublication in Cancer Research]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies

 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Dicer Ablation Impairs Prostate Stem Cell Activity and Causes Prostate Atrophy
To gain insight into the role of microRNAs in prostate tissue function and homeostasis, researchers conditionally disrupted Dicer activity in the mouse prostate using an ARR2PB-Cre system and demonstrated that Dicer activity is disrupted in both prostatic basal/stem cells and differentiated luminal cells. [Stem Cells]

Predicting the Site of Origin of Tumors by a Gene Expression Signature Derived from Normal Tissues
Whereas in past studies, cancer of unknown primary origin (CUP) classifiers were trained solely on data from tumor samples, researchers now use expression patterns from normal tissues for classifier training. [Oncogene]

Transgenic Expression of 15-Lipoxygenase 2 (15-LOX2) in Mouse Prostate Leads to Hyperplasia and Cell Senescence
To better understand the biological role of 15-lipoxygenase 2 (15-LOX2) in vivo, researchers generated 15-LOX2 transgenic mice using the ARR2PB promoter. [Oncogene]

Copy Number Variation in Glutathione-S-Transferase T1 and M1 Predicts Incidence and 5-Year Survival from Prostate and Bladder Cancer, and Incidence of Corpus Uteri Cancer in the General Population
Researchers determined the ability of glutathione-S-transferase copy number variation to predict the risk of cancer in the general population. [Pharmacogenomics J]

Genomic Profiling of Tumor Initiating Prostatospheres
Researchers intended to establish a comprehensive culture system to grow prostatospheres from both cancer cell lines and patient tumors. They then used gene expression microarrays to gain insight on the molecular pathways that sustain the prostatospheres tumor initiating cell phenotype. [BMC Genomics]

Slug/SNAI2 Regulates Cell Proliferation and Invasiveness of Metastatic Prostate Cancer Cell Lines
The data imply that SNAI2 exerts strong effects on the cytoskeleton and adhesion of those prostate cancer cells that express it and is necessary for their proliferation and invasiveness. [Tumour Biol]

Studies on Molecular Mechanisms of Growth Inhibitory Effects of Thymoquinone Against Prostate Cancer Cells: Role of Reactive Oxygen Species
Researchers investigated the mechanism of action of thymoquinone in androgen receptor (AR)-independent (C4-2B) and AR naïve (PC-3) prostate cancer cells, as models of aggressive prostate cancers. [Exp Biol Med]

CLINICAL RESEARCH

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates. [J Clin Oncol]

Calcium Intake Increases Risk of Prostate Cancer among Singapore Chinese
Researchers examined calcium intake and prostate cancer risk among 27,293 men in the Singapore Chinese Health Study that was established between 1993 and 1998. [Cancer Res]



INDUSTRY NEWS

Extension Study With FIRMAGON® (Degarelix) Showed Continued Benefits For Prostate Cancer Patients Beyond One Year
Prostate cancer patients on leuprolide who were offered to continue on FIRMAGON® (degarelix for injection) after one year of treatment reduced prostate specific antigen (PSA) recurrence, according to results of a Phase III extension study. [Medical News Today]



POLICY NEWS

Treasury Releases New Guidance for Tax Credit in Affordable Care Act to Support Groundbreaking Biomedical Research
The U.S. Department of the Treasury announced the guidelines for applying for the new Therapeutic Discovery Project Program created by the Affordable Care Act. [Department of the Treasury, United States]

Third Time’s a Charm for COMPETES Bill
By a vote of 262 to 150, legislators authorized $84 billion for research, education, and innovation programs over the next 5 years at the National Science Foundation, the Department of Energy, and two Department of Commerce agencies – NOAA and NIST under the America COMPETES Reauthorization Act (HR 5116). [House of Representatives, United States]

Democrats: FDA Should Be Able to Recall Drugs
House Democrats repeatedly called for federal regulators to be given the authority to recall drugs. Pending legislation would grant that power to the Food and Drug Administration (FDA) for food, but not for drugs. [House of Representatives, United States]

Last Hurrah from National Academies Stem Cell Committee
Even though the National Institutes of Health issued stem cell guidelines last year, there’s still a need for guidelines for research that remains off-limits for U.S. government-funded labs. [National Academies’ National Research Council and Institute of Medicine, United States]

NIH Set to Tighten Financial Rules for Researchers
After a wave of financial scandals over the past few years involving biomedical researchers, the U.S. National Institutes of Health (NIH) proposed far-reaching changes that would lead to tighter oversight of agency-funded extramural investigators and their institutions. [National Institutes of Health, United States]

Request for Information (RFI) on the NIH Plan to Develop the Genetic Testing Registry (NOT-OD-10-101)
[National Institutes of Health, United States]

Administrative Supplements to Advance Special Translational Research Acceleration Projects on Immune Response Modifiers Currently Funded by the National Cancer Institute (NCI) (NOT-CA-10-025) [National Institutes of Health, United States]



EVENTS

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us